Search research articles
Contact Us
Filters
Showing results (141-150 of 171) with videos related to
Page
of 18
Sort By:
Nature Communications
|
March 17, 2026
Implantable soft bladder-machine interface for neurogenic bladder dysfunction
Hanfei Li, Shuai Wang, Qianhengyuan Yu, et al.
The Oncologist
|
March 24, 2019
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai-Ping Zhou, Yuxian Bai, Yan Song, et al.
Scientific Reports
|
July 20, 2024
PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer
Yu Fan, Tao Dai, Dahong Zhang, et al.
Aging
|
February 3, 2020
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer
Guoliang Wang, Yi Huang, Feilong Yang, et al.
Scientific Reports
|
December 24, 2022
Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems
Lingfeng Meng, Zijian Tian, Yaoguang Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
October 4, 2016
Ectopic Cushing's syndrome due to retroperitoneal ACTH-producing paragangliomas
Fan Chen, Xiangyu Wang, Yang Wang, et al.
Journal of Cancer Research and Clinical Oncology
|
September 6, 2023
Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging
Hao Liang, Qingya Yang, Yaozhong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng, Xieqiao Yan, Lin Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
Wang Qu, Cheng Fu, Weiqing Han, et al.
Frontiers in Medicine
|
April 10, 2023
Sacral neuromodulation remote programming in patients with refractory lower urinary tract dysfunction: China's experience during the COVID-19 pandemic
Lingfeng Meng, Huimin Hou, Peng Zhang, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 171) with videos related to
Sort By:
Page
of 18
Nature Communications
|
March 17, 2026
Implantable soft bladder-machine interface for neurogenic bladder dysfunction
Hanfei Li, Shuai Wang, Qianhengyuan Yu, et al.
The Oncologist
|
March 24, 2019
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Ai-Ping Zhou, Yuxian Bai, Yan Song, et al.
Scientific Reports
|
July 20, 2024
PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer
Yu Fan, Tao Dai, Dahong Zhang, et al.
Aging
|
February 3, 2020
High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer
Guoliang Wang, Yi Huang, Feilong Yang, et al.
Scientific Reports
|
December 24, 2022
Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems
Lingfeng Meng, Zijian Tian, Yaoguang Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
October 4, 2016
Ectopic Cushing's syndrome due to retroperitoneal ACTH-producing paragangliomas
Fan Chen, Xiangyu Wang, Yang Wang, et al.
Journal of Cancer Research and Clinical Oncology
|
September 6, 2023
Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging
Hao Liang, Qingya Yang, Yaozhong Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng, Xieqiao Yan, Lin Wang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
Wang Qu, Cheng Fu, Weiqing Han, et al.
Frontiers in Medicine
|
April 10, 2023
Sacral neuromodulation remote programming in patients with refractory lower urinary tract dysfunction: China's experience during the COVID-19 pandemic
Lingfeng Meng, Huimin Hou, Peng Zhang, et al.
Page
of 18